EGFR and cancer: Inhibition of abnormal ERK activities in these cancer cells by canertinib (an EGFR inhibitor), vemurafenib (a BRaf inhibitor), or trametinib (a MEK inhibitor) treatment abrogated their expression (Fig. 7e).